Galderma/Ipsen's Azzalure cleared in the UK

Galderma, a Swiss dermatology-focused drugmaker, and French firm Ipsen say that Azzalure (botulinum toxin Type A), a muscle relaxant  specifically developed for esthetic use, has received a marketing  authorization in the UK from the Medicines and Healthcare products  Regulatory Agency (MHRA) for the temporary improvement in the appearance  of moderate-to-severe glabellar lines seen at the frown (vertical lines  between the eyebrows), in adult men and women aged 65 years and under,  when the severity of these lines has an important psychological impact  on the patient. Azzalure is adapted from Dysport (botulinum toxin  type-A), which is already marketed by Ipsen for therapeutic indications  and has a 20-year safety record. The product will be commercially  available in the UK by the second quarter of 2009.